Étude pilote d’un nouvel agent de thérapie matricielle (RGTA OTR4120®) dans les ulcères de cornée et les dystrophies cornéennes rebelles

Chebbi, C. Khammari; Kichenin, Ketty; Amar, N.; Nourry, H.; Warnet, Jean‐Michel; Barritault, Denis; Baudouin, Christophe

doi:10.1016/s0181-5512(08)72462-8

Cited by 48 publications

(15 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, in these reports and in ongoing studies, RGTA ® was well tolerated, and no adverse side effects have been reported. In line with our observations in patients with chronic wounds, patients treated for corneal injuries also experienced decreased pain [69], which may reflect the anti-inflammatory properties of RGTA ® .…”

Section: Rgta® In the Clinicsupporting

confidence: 89%

“…In a study of patients with severe corneal neurotrophic ulcers, treatment with RGTA ® (every 2 days) led to complete corneal healing in 8 out of 11 patients after approximately 9 weeks [65], supporting previous observations in individual patients presenting with neurotropic ulcers [66, 68]. In a second study involving 10 patients with severe corneal dystrophy or corneal ulcers, weekly treatment with RGTA ® over the course of 1 month led to improved healing and inflammation of most ulcers, and this was associated with reduced pain [69]. In this study, optimisation of the dose and number of treatments is needed however, since these effects were reversed in several patients following termination of treatment.…”

Section: Rgta® In the Clinicsupporting

confidence: 69%

“…[68] Persistant epithelial ulcers−11 eyes treated, pain relief and improvement in 9 cases.Chebbi et al . [69] Limbal graft failure-Successful limbal allografts after previous failures.Maringe et al . [70] Corneal perforation associated with Sjogren’s disease-Corneal healing in all five treated patients.Renault et al .…”

Section: Rgta® In the Clinicmentioning

confidence: 99%

See 2 more Smart Citations

RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients

et al. 2016

View full text Add to dashboard Cite

The importance of extracellular matrix (ECM) integrity in maintaining normal tissue function is highlighted by numerous pathologies and situations of acute and chronic injury associated with dysregulation or destruction of ECM components. Heparan sulfate (HS) is a key component of the ECM, where it fulfils important functions associated with tissue homeostasis. Its degradation following tissue injury disrupts this delicate equilibrium and may impair the wound healing process. ReGeneraTing Agents (RGTA®s) are polysaccharides specifically designed to replace degraded HS in injured tissues. The unique properties of RGTA® (resistance to degradation, binding and protection of ECM structural and signaling proteins, like HS) permit the reconstruction of the ECM, restoring both structural and biochemical functions to this essential substrate, and facilitating the processes of tissue repair and regeneration. Here, we review 25 years of research surrounding this HS mimic, supporting the mode of action, pre-clinical studies and therapeutic efficacy of RGTA® in the clinic, and discuss the potential of RGTA® in new branches of regenerative medicine.

show abstract

Section: Rgta® In the Clinicsupporting

confidence: 89%

Section: Rgta® In the Clinicsupporting

confidence: 69%

See 1 more Smart Citation

RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…CACICOL20 is successfully used to treat corneal dystrophies as well as corneal ulcers resistant to standard treatment. Chebbi et al [ 4 ] presented 11 cases with severe corneal dystrophies and painful corneal ulcers with good results in healing. De Monchy et al [ 5 ] reported a case of neurotrophic herpes ulcer successfully treated in 3 weeks with topical RGTA.…”

Section: Resultsmentioning

confidence: 99%

Treatment of Acanthamoeba neurotrophic corneal ulcer with topical matrix therapy

Mateo

Abadia

Calvo

et al. 2015

J Ophthal Inflamm Infect

View full text Add to dashboard Cite

BackgroundThis study was done to evaluate the visual and anatomical outcomes of topical regenerating agents as a novel therapy for neutrophic corneal ulcer (NCU) secondary to acanthamoeba infection.FindingsA 20-year-old woman with a history of contact lens wear was referred to our hospital for keratitis after responding poorly to conventional treatment. In vivo confocal microscopy images suggested acanthamoeba keratitis with double-walled cysts in the anterior corneal stroma. Acanthamoeba infection was confirmed by laboratory findings. She was started on 0.1 % propamidine and 0.02 % chlorhexidine drops every hour. The antibiotic and antifungal drops were stopped when bacterial and fungal cultures proved negative. A central neurotrophic corneal ulcers (NCU) appeared, and despite treatment with artificial tears, bandage contact lens, and autologous serum, the ulcer worsened and she was treated with topical CACICOL20 (1 drop every 2 days) for 8 weeks. The corneal defect was completely repaired in 3 weeks. The treatment was well tolerated, and no local or systemic side effects were noted. Visual acuity remained 20/400. Two months later, the defect was still closed and the patient continued with 0.1 % propamidine and 0.02 % chlorhexidine drops, bandage contact lens, artificial tears, and autologous serum.ConclusionsTopical regenerating agents interact with components of the extracellular matrix, binding matrix proteins and protecting them from proteolysis, restoring the matrix environment, and improving tissue healing. In this case, CALCICOL20 was effective for vision stabilization, wound healing, and was well tolerated for NCU secondary to acanthamoeba infection.

show abstract

“…By binding to structural matrix proteins (collagen, elastin, fibronectin), the scaffolding properties of the ECM, and the mechanical protection of the matrix signaling proteins (heparin-binding growth factors, cytokines, neurotrophic factors) against proteolytic degradation, are restored [ 12 ]. This, in turn, prevents the degradation of the extracellular matrix proteins, and promotes stromal and, subsequently, epithelial healing [ 13 , 14 ].…”

Section: Regenerating Agents (Rgta)mentioning

confidence: 99%

Matrix regenerative therapy

Cm¹,

Stefan²,

Da³

et al. 2017

rjo

View full text Add to dashboard Cite

The extracellular matrix (ECM) is responsible for many of the cell behavior processes, including cell proliferation and growth, survival, change in cell shape, migration, and differentiation. The most important component of the ECM is heparan sulfate (HS), because it insures the storage of many cell communication proteins, necessary for the continuous and identical renewal of cells and thus for tissue regeneration. Regenerating agents (RGTA®) are bioengineered structural analogues of heparan sulfate glycosaminoglycans that replace the degraded endogenous HS of the ECM. In the ophthalmological field, RGTA® represents an innovative approach for the improvement of the ocular surface wound healing and matrix remodeling and plays a role in controlling and regulating the wound healing process in various ocular diseases.

show abstract

Étude pilote d’un nouvel agent de thérapie matricielle (RGTA OTR4120®) dans les ulcères de cornée et les dystrophies cornéennes rebelles

Cited by 48 publications

References 36 publications

RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients

RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients

Treatment of Acanthamoeba neurotrophic corneal ulcer with topical matrix therapy

Matrix regenerative therapy

Contact Info

Product

Resources

About